Diagnosis

The road from "something is different" to "the gene is DLL1."

There is no DLL1 blood test. There is no scan that says "this is the one." The diagnosis is made by reading DNA — and then, often, by re-reading it.

The three doors: how genetic testing finds DLL1

Targeted

Single-gene test

DLL1 sequencing

Reads only DLL1. Useful when the picture so strongly suggests DLL1 that no other gene is worth checking — essentially never as a first step. Most families do not start here.

CoverageDLL1 only
Best forFamily follow-up
MissesEverything else
Broad panel

Neurodevelopmental panel

ID / autism / epilepsy gene panel

Reads dozens to thousands of NDD genes. DLL1 is on most modern panels — but newer additions are sometimes missing from older test reports.

CoverageCurated gene list
Best forFirst-line testing
Watch forPanel age & gene list
Most likely to detect

Whole-exome / genome

WES · WGS · trio recommended

Reads all protein-coding regions (exome) or the entire genome. Highest-yield test for unexplained NDD. Most published DLL1 cases were identified by trio exome — child plus both parents.

CoverageAll protein-coding genes
Best forUnsolved cases
BonusReanalyzable later

What the diagnostic process typically looks like

  1. Clinical evaluation. A medical geneticist, developmental pediatrician, or neurologist assesses growth, neurological exam, dysmorphic features, family history, and prior imaging — and decides which tests to order or revisit.
  2. Chromosomal microarray and/or exome. First-tier testing for global delay or ID is typically a chromosomal microarray (CMA) — which can detect deletions including those at 6q27 — plus, increasingly, trio exome sequencing. CMA catches the big deletions; exome catches the smaller variants.
  3. Variant identification. The lab returns a report with the gene, the specific change (e.g., c.1234C>T, p.Arg412Ter), inheritance from the trio, and an interpretation classification.
  4. Variant classification. Each variant is graded on a five-point scale (below). A "likely pathogenic" or "pathogenic" DLL1 variant with appropriate clinical features is the formal diagnosis. A VUS means the variant is real but its disease-causing role isn’t yet established.
  5. Confirmation & family testing. The finding is confirmed and parents tested to establish whether the variant arose de novo or was inherited. This shapes recurrence-risk counseling and any sibling testing.

ACMG variant classification — the five categories

i
Benign
Does not cause disease
ii
Likely Benign
Probably harmless
iii
VUS
Uncertain · needs more evidence
iv
Likely Pathogenic
Probably causes disease
v
Pathogenic
Disease-causing

If your testing was done before 2019: reanalysis

DLL1 was only formally established as a disease gene in 2019. Anyone tested before that — or with a panel that didn’t yet include DLL1 — should know the data may still be on the lab’s server, waiting to be re-read.

Most major labs (GeneDx, Invitae, others) offer reanalysis, often at low or no cost, when a clinician submits a formal request. Many recheck against new gene–disease associations every 1–2 years; others require an explicit nudge.

A practical checklist for requesting reanalysis

  1. Locate the original test report: which lab, which test, what year.
  2. Confirm the test was an exome or genome (not a small targeted panel).
  3. Ask your genetic counselor or geneticist to submit reanalysis through the lab’s clinician portal.
  4. Mention genes of interest specifically — DLL1 (6q27), plus others relevant to the picture.
  5. Provide updated phenotype information observed since the original test.
  6. Ask whether trio reanalysis (re-running parents alongside) is possible.
  7. Be prepared for the answer to be the same as before — and for it, sometimes, not to be.

Working with a genetic counselor

A genetic counselor translates genetic information into something families can act on. For a rare condition like DLL1-related disorder, this is often the most important relationship in the diagnostic journey.

Questions worth asking aloud

  • Is the variant pathogenic, likely pathogenic, or a VUS — and what does that mean for us?
  • Did the variant arise de novo, or is it inherited?
  • What’s the recurrence risk for future pregnancies?
  • What surveillance do you recommend, given what’s known?
  • Are there research studies enrolling DLL1 families right now?
  • Will my child’s data — de-identified — be added to any registries?
  • If the result is uncertain, when would you re-check it?
  • Who else should I be in touch with — neurology, orthopedics, developmental pediatrics?

You can find a counselor through the National Society of Genetic Counselors directory, your geneticist’s clinic, or your testing laboratory — most labs provide complimentary post-result counseling.

From diagnosis to the research frontier

Once you have a DLL1 result, the next reasonable question is: what do we actually know? See the research page for the published papers, active questions, and labs to follow — or visit Newly Diagnosed for what to do in the first hours, days, and weeks.

Connect with us →